Cadent Therapeutics is creating breakthrough therapies for the treatment of movement disorders and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 1 clinical studies for the treatment of treatment-resistant depression.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/17/18 | $40,000,000 | Series B |
Access Industries Atlas Venture Clal Biotechnology Industries Cowen Healthcare Investments  Novartis Institute for Biomedical Research Qiming Venture Partners | undisclosed |
